NCT02113878 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 23
- units
- Participants
- groups
- description
- * 40 mg BKM120 will be administered orally daily for 45 days. Starting dose 40 mg. * Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43). * Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks. BKM120: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor. Cisplatin: Cisplatin is a chemotherapy drug Intensity-modulated radiotherapy (IMRT): IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
- id
- BG000
- title
- Dose Level 1
- description
- * 40 mg BKM120 will be administered orally daily for 45 days. * Cisplatin: Starting Dose 35 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43). * Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks. BKM120: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor. Cisplatin: Cisplatin is a chemotherapy drug Intensity-modulated radiotherapy (IMRT): IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
- id
- BG001
- title
- Dose Level 2
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 7.1
- value
- 63.7
- group Id
- BG001
- spread
- 4.17
- value
- 57.2
- group Id
- BG002
- spread
- 7.02
- value
- 62.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Female
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 19
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 21
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 22
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Clinical Cancer Stage 3
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 21
- title
- Clinical Cancer Stage 4
- description
- Either of the following indicate Stage 3: * It is at least 4 cm across, and no cancer cells are present in nearby structures, lymph nodes or distant sites. * It is any size but has not grown into nearby structures or distant sites. Cancer cells are present in one same-side lymph node and is at most 3 cm across. Any of the following indicate Stage 4: * Grown into nearby structures * Grown into deeper tissue * Has spread to multiple lymph nodes * Has spread to one lymph node and is either at least 3cm on the same side or at least 6cm on the opposite side.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Stage
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Hypopharynx
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 6
- title
- Oral Cavity
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 12
- title
- Oropharynx
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- title
- Larynx
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Oth
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Primary Disease Site
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 23
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- No
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Smoking History
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 22
- title
- Greater than 10
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Less than or equal to 10
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of Pack Years
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 18
- title
- No
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Current Smoker
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 23
- units
- Participants
- groups
- description
- * 40 mg BKM120 will be administered orally daily for 45 days. Starting dose 40 mg. * Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43). * Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks. BKM120: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor. Cisplatin: Cisplatin is a chemotherapy drug Intensity-modulated radiotherapy (IMRT): IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
- id
- BG000
- title
- Dose Level 1
- description
- * 40 mg BKM120 will be administered orally daily for 45 days. * Cisplatin: Starting Dose 35 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43). * Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks. BKM120: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor. Cisplatin: Cisplatin is a chemotherapy drug Intensity-modulated radiotherapy (IMRT): IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
- id
- BG001
- title
- Dose Level 2
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 7.1
- value
- 63.7
- group Id
- BG001
- spread
- 4.17
- value
- 57.2
- group Id
- BG002
- spread
- 7.02
- value
- 62.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Female
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 19
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 21
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 22
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Clinical Cancer Stage 3
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 21
- title
- Clinical Cancer Stage 4
- description
- Either of the following indicate Stage 3: * It is at least 4 cm across, and no cancer cells are present in nearby structures, lymph nodes or distant sites. * It is any size but has not grown into nearby structures or distant sites. Cancer cells are present in one same-side lymph node and is at most 3 cm across. Any of the following indicate Stage 4: * Grown into nearby structures * Grown into deeper tissue * Has spread to multiple lymph nodes * Has spread to one lymph node and is either at least 3cm on the same side or at least 6cm on the opposite side.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Stage
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Hypopharynx
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 6
- title
- Oral Cavity
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 12
- title
- Oropharynx
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- title
- Larynx
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Oth
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Primary Disease Site
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 23
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- No
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Smoking History
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 22
- title
- Greater than 10
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Less than or equal to 10
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of Pack Years
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 18
- title
- No
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Current Smoker
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle